KCAS Bio will be attending MetroFlow 2025 Annual Meeting, taking place October 23 in New York, NY.
The MetroFlow 2025 Annual Meeting brings together a dedicated community of flow cytometry professionals, including core facility directors, technical experts, researchers, and service providers. As such, this gathering provides a collaborative environment to explore the scientific and operational aspects of cytometry-based technologies. Attendees will engage in meaningful discussions on best practices for assay standardization, data reproducibility, and the translational application of cytometry in drug development and clinical research.
While advancements in high-dimensional cytometry, single-cell analysis, and data integration continue to shape the field, the meeting offers a valuable platform to exchange insights and share challenges in this critical area of bioanalysis.
Flow Cytometry at KCAS Bio
KCAS Bio applies advanced flow cytometry techniques to support complex drug development programs, with expertise in cell and gene therapy, immunophenotyping, and biomarker analysis. Our scientists design and validate custom assays to characterize immune cell populations, evaluate cellular responses, and generate high-dimensional data. Furthermore, with a strong focus on data quality and regulatory alignment, our flow cytometry capabilities are built to meet the demands of modern therapeutic development.
Looking Forward in Flow Cytometry
Our teams stay at the forefront of instrumentation, panel design, and data analysis tools to ensure we deliver robust and regulatory-ready results. As the field continues to evolve toward higher-dimensional data and more clinically relevant applications, KCAS Bio is committed to pushing the boundaries of what flow cytometry can deliver in both discovery and translational research.
In alignment with this commitment, attending the MetroFlow 2025 Meeting supports KCAS Bio’s dedication to staying current with advancements in flow cytometry. Through active engagement with experts across the field, we continue to refine our capabilities and apply the latest technologies to meet the needs of complex drug development programs.
Connect With Us at The MetroFlow 2025 Meeting
We invite you to connect with us throughout the meeting day to discuss the goals, complexities, and opportunities within your ongoing or upcoming projects. Our team member, Karla Moncada, will be present and ready to discuss our flow cytometric approaches. She looks forward to exploring how KCAS Bio can provide personalized solutions to your custom needs.